Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314
收藏DataCite Commons2020-09-20 更新2024-07-13 收录
下载链接：
https://medical-data-models.org/28181
下载链接
链接失效反馈官方服务：
资源简介：
NCT02641314
Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB).
The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected.
Prof. Dr. Frank Berthold
Abt. für Kinderonkologie und –hämatologie
Zentrum für Kinder- und Jugendmedizin
Universität zu Köln
提供机构：
Medical-Data-Models.org
创建时间：
2018-11-13
